UK biotech startup Mogrify injects $16M to get novel cell therapies to market soon

Cambridge, UK-based biotech startup Mogrify, which is working on systematizing the development of novel cell therapies in areas such as regenerative medicine, has closed an initial $16 million Series A. The raise from investors Ahren Innovation Capital, Parkwalk and 24Haymarket follows a $4M seed in February -- taking its total raised to date to $20M. Put simply, Mogrify's approach entails analysis of vast amounts of genomic data in order to identify the specific energetic changes needed to flip an adult cell from one type to another without having to reset it to a stem cell state -- with huge potential utility for a wide variety of therapeutic use-cases.